HLB PharmaceuticalHLB제약
047920 · KOSDAQ · ₩047920 · HLB제약
- Market cap
- ₩431B
- Enterprise value
- ₩427B
- P/E
- 156.3×
- P/B
- 3.3×
- Dividend yield
- 0.0%
- ROE
- 2.1%
- Net margin
- 1.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−55.6% from the high
₩6,000Today: ₩9,600 – ₩10,190₩22,250
Returns
- 1W−8.3%
- 1M+33.6%
- 3M+18.6%
- 6M−44.1%
- YTD−38.3%
- 1Y−35.8%
- Volume today
- 235,434
- 0.1× the 20-day average
- Traded today
- ₩2.3B
- Listed shares
- 43,561,688
- EPS (12 months)
- ₩63
- Earnings yield 0.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumFlat32.9% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Knock-on effects
Knock-on from news elsewhere
HLB · [BioS] HLB, After FDA Approval of 'Rifitu,' Announces Group Mid-to-Long-Term Strategy
Moves with HLB (corr 0.87); moved with HLB on 15 of its 16 biggest days
News about other companies that has, in the past, moved this stock too. Evidence-based, not a prediction.
HLB Pharmaceutical stock overview
HLB Pharmaceutical (HLB제약, KRX: 047920) is listed on KOSDAQ, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩9,890 on Oct 27, 2026, up 1.64% on the day, giving it a market value of ₩431B.
Key facts
- Market cap
- ₩431B
- Sector
- Biotech & Pharma
- Latest price change
- +1.64%
- As of
- Oct 27, 2026
- Main business
- , Ltd.
Quick answers about HLB Pharmaceutical
- What does HLB Pharmaceutical do?
- , Ltd. is a Korean drugmaker, originally founded in 1998 as Citree and renamed after joining the HLB Group in 2020, that manufactures and sells prescription drugs, provides contract manufacturing (CMO) services, and sells health functional foods. Its main products include Rosuduo, Citclear, and Citrelin, which it sells mainly through contract sales in the prescription drug market, and it is developing long-acting injectable drug delivery technologies at its Dongtan research center.
- What is the market cap of HLB Pharmaceutical?
- The market capitalisation of HLB Pharmaceutical was ₩431B at the close on Oct 27, 2026.
- Who are the largest shareholders of HLB Pharmaceutical?
- According to the latest official filings, the largest reported holders are HLB Life Science (18.97%, as of Oct 21, 2026); Jin Yang-gon (2.78%, as of Aug 27, 2026); Park Jae-hyung (1.51%, as of Sep 28, 2026).
- When is the next earnings report from HLB Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when HLB Pharmaceutical filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
HLB Pharmaceutical Co., Ltd. is a Korean drugmaker, originally founded in 1998 as Citree and renamed after joining the HLB Group in 2020, that manufactures and sells prescription drugs, provides contract manufacturing (CMO) services, and sells health functional foods. Its main products include Rosuduo, Citclear, and Citrelin, which it sells mainly through contract sales in the prescription drug market, and it is developing long-acting injectable drug delivery technologies at its Dongtan research center. In May 2025 it acquired 100% of Shinhwa Advance, adding a pharmaceutical distribution business, and it operates from Seoul with manufacturing in Nam-yangju and Hwaseong.
Written by AI from the company's latest annual report.
- Korean name
- HLB제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 박재형
- Founded
- Apr 1998
- Listed
- Dec 2015
- Listed shares
- 43,561,688
- Fiscal year ends
- Month 12
- Website
- www.hlbpharma.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- 5%+ holding reportOct 21, 2026
- Investor relations (IR) eventOct 12, 2026
- New Facility Investment, etc.Oct 1, 2026
- 5%+ holding reportSep 28, 2026
- Insider shareholding reportSep 28, 2026
Titles in Korean until English translations are added.
Also known as: HLB Pharmaceutical / HLB제약 / 047920 / KRX:047920
Source: KRX statistical information